Bavar­i­an Nordic's pur­chase of Emer­gen­t's late-stage Chikun­gun­ya vac­cine pays off in PhI­II read­out

A late-stage Chikun­gun­ya vac­cine that Bavar­i­an Nordic bought from Emer­gent BioSo­lu­tions ear­li­er this year has suc­ceed­ed in a first read­out from a Phase III tri­al, the Dan­ish com­pa­ny said.

In the tri­al, 87% of peo­ple aged 65 and old­er who got the vac­cine showed suf­fi­cient neu­tral­iz­ing an­ti­bod­ies, the com­pa­ny said in a press re­lease, meet­ing one of the pri­ma­ry end­points. Just over 400 peo­ple were en­rolled in the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER